|
시장보고서
상품코드
2036433
첨단 치료용 의약품(ATMP) CDMO 시장 규모, 점유율, 성장 분석 : 치료법별, 서비스 유형별, 용도별, 사업 규모별, 지역별 - 업계 예측(2026-2033년)Advanced Therapy Medicinal Products CDMO Market Size, Share, and Growth Analysis, By Therapy Type (Gene Therapy, Cell Therapy), By Service Type, By Application, By Scale of Operation, By Region - Industry Forecast 2026-2033 |
||||||
세계의 첨단 치료 의약품 CDMO 시장 규모는 2024년에 67억 1,000만 달러로 평가되며, 2025년 79억 8,000만 달러에서 2033년까지 319억 2,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 18.92%로 성장할 것으로 전망되고 있습니다.
세계의 첨단치료제 위탁개발 및 생산기관(CDMO) 시장은 세포 및 유전자 치료제 파이프라인 증가에 따른 전문 제조 역량에 대한 수요 증가로 인해 크게 성장하고 있습니다. 이러한 CDMO는 복잡한 생물제제를 임상 적용으로 이끄는 역할을 담당하고 있으며, 이를 위해서는 개별화된 클린룸 환경과 엄격한 품질 보증 프로토콜이 필수적입니다. 이 분야는 소규모 학술연구용 GMP 시설에서 대규모 상업 조직으로 변모하고 있으며, 유전자 치료제 승인 건수가 증가함에 따라 생산 능력 확대가 필수적임을 강조하고 있습니다. 이러한 추세는 혁신적인 제조 기술 및 자동화에 대한 막대한 투자를 촉진하여 생산 주기 시간을 단축하고 확장성을 높이는 동시에 생산성을 향상시키고 있습니다. 제조 공정에 AI를 통합하면 효율성을 더욱 높이고, 운영을 간소화하며, 고품질 결과를 보장함으로써 더 많은 투자를 유치하고, 첨단 치료법에 대한 지역적 접근성을 확대할 수 있습니다.
세계의 첨단치료제 CDMO 시장 성장 요인
개인맞춤형 치료와 세포치료에 대한 관심이 높아짐에 따라 전 세계 첨단치료제 CDMO 시장에서 전문적 제조 노하우에 대한 수요가 확대되고 있습니다. 개발자들이 개별화된 치료 접근법으로 전환함에 따라 복잡한 공정 관리, 맞춤형 배치 제조, 섬세한 생물학적 물질을 다룰 수 있는 외부 파트너에 대한 의존도가 높아지고 있습니다. 이러한 필요성은 CDMO 부문내 전문 시설, 숙련된 전문가 및 고급 역량에 대한 투자를 촉진하고 있습니다. 이러한 파트너십을 통해 내부 인프라를 구축하지 않고도 첨단 기술에 대한 접근성을 제공함으로써 프로그램의 빠른 진행을 촉진하고, 첨단 치료제의 상업적 기회를 확대할 수 있습니다.
세계의 첨단치료제 CDMO 시장 억제요인
세계의 첨단치료제 CDMO 시장은 각 관할권의 엄격하고 끊임없이 변화하는 규제 프레임워크로 인해 상당한 도전에 직면해 있습니다. 이러한 규제는 계약개발생산기관(CDMO)과 그 고객에게 큰 컴플라이언스 부담을 부과하고, 그 결과 프로젝트 일정이 길어지고 업무의 복잡성을 증가시키고 있습니다. 다양한 규제 요건을 충족하기 위해서는 첨단 전문 지식, 방대한 문서화, 엄격한 프로세스 검증이 필요하며, 이는 혁신과 사업 확장을 위한 노력에서 주의와 자원을 분산시킬 수 있습니다. 또한 새로운 치료법에 대한 요구사항에 대한 불확실성은 투자에 대한 신중함을 불러일으키고 기술 이전을 복잡하게 만들어 첨단 치료법 개발자를 지원할 수 있는 공급자의 선택권을 제한하고 있습니다. 결과적으로 이러한 규제의 복잡성은 시장 성장의 장벽이 되어 진입장벽을 높이고 개발 주기를 장기화시키고 있습니다.
세계의 첨단치료제 CDMO 시장 동향
세계의 첨단치료제 CDMO 시장에서는 모듈식 제조를 채택하는 경향이 두드러지게 나타나고 있습니다. 이러한 변화는 다양한 세포치료제 및 유전자치료제에 대응할 수 있도록 신속한 재구성이 가능한 유연한 시설 설계의 도입으로 특징지어집니다. 표준화된 플러그 앤 플레이 방식의 모듈은 엄격한 품질관리를 유지하면서 신속한 기술 이전과 확장 가능한 생산 능력의 배포를 가능하게 합니다. 이러한 아키텍처적 접근 방식은 변화하는 고객 니즈에 대한 대응력을 높이고, 상용화까지의 시간을 단축하며, 반복 가능한 프로세스와 예측 가능한 프로젝트 일정을 촉진하는 플랫폼적 사고를 촉진합니다. 이를 통해 기업은 치료법의 발전과 전략적 투자 동향에 맞춰 생산 능력을 조정할 수 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 첨단 치료용 의약품(ATMP) CDMO 시장 규모 : 치료 유형별
세계의 첨단 치료용 의약품(ATMP) CDMO 시장 규모 : 서비스 유형별
세계의 첨단 치료용 의약품(ATMP) CDMO 시장 규모 : 용도별
세계의 첨단 치료용 의약품(ATMP) CDMO 시장 규모 : 사업 규모별
세계의 첨단 치료용 의약품(ATMP) CDMO 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSAGlobal Advanced Therapy Medicinal Products Cdmo Market size was valued at USD 6.71 Billion in 2024 and is poised to grow from USD 7.98 Billion in 2025 to USD 31.92 Billion by 2033, growing at a CAGR of 18.92% during the forecast period (2026-2033).
The global market for advanced therapy medicinal products contract development and manufacturing organizations (CDMOs) is significantly driven by the burgeoning demand for specialized manufacturing capabilities due to the rising cell and gene therapy pipelines. These CDMOs facilitate the translation of complex biologics into clinical applications, necessitating tailored cleanroom environments and stringent quality assurance protocols. The sector has transformed from small academic GMP setups to large-scale commercial entities, underscoring the essential need for capacity expansion amidst increasing approvals for gene therapies. This trend has spurred substantial investments in innovative manufacturing technologies and automation, reducing production cycle times while enhancing scalability. The integration of AI in manufacturing processes further amplifies efficiency, streamlining operations, and ensuring high-quality outputs, subsequently attracting more investment and geographic access to advanced therapies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Advanced Therapy Medicinal Products Cdmo market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Advanced Therapy Medicinal Products Cdmo Market Segments Analysis
Global advanced therapy medicinal products cdmo market is segmented by therapy type, service type, application, scale of operation and region. Based on therapy type, the market is segmented into Gene Therapy, Cell Therapy, Tissue Engineered Products, Combined ATMPs and Others. Based on service type, the market is segmented into Process Development, Analytical Development, Clinical Manufacturing, Commercial Manufacturing, Fill-Finish Services and Others. Based on application, the market is segmented into Oncology, Rare Diseases, Cardiovascular Diseases, Neurological Disorders and Others. Based on scale of operation, the market is segmented into Clinical Scale and Commercial Scale. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Advanced Therapy Medicinal Products Cdmo Market
The increasing focus on personalized and cell-based therapies is fueling the demand for specialized manufacturing expertise within the global Advanced Therapy Medicinal Products CDMO market. As developers shift towards individualized treatment approaches, there is a growing reliance on external partners capable of managing intricate processes, producing customized batches, and handling sensitive biological materials. This necessity drives investment in specialized facilities, skilled professionals, and advanced capabilities within the CDMO sector. By providing access to cutting-edge technologies without the need for in-house infrastructure, these partnerships facilitate the rapid advancement of programs and expand the commercial opportunities for advanced therapy medicinal products.
Restraints in the Global Advanced Therapy Medicinal Products Cdmo Market
The Global Advanced Therapy Medicinal Products CDMO market faces notable challenges due to stringent and constantly changing regulatory frameworks in various jurisdictions. These regulations impose significant compliance burdens, resulting in extended project timelines and heightened operational complexity for Contract Development and Manufacturing Organizations (CDMOs) and their clients. The necessity to meet diverse regulatory demands requires substantial expertise, extensive documentation, and rigorous process validation, which can divert attention and resources from innovations and expansion initiatives. Additionally, uncertainty surrounding requirements for new therapeutic modalities fosters cautious investment and complicates technology transfer, thereby limiting the pool of providers available to support advanced therapy developers. As a result, this regulatory complexity acts as a barrier to market growth, raising entry hurdles and prolonging development cycles.
Market Trends of the Global Advanced Therapy Medicinal Products Cdmo Market
The Global Advanced Therapy Medicinal Products CDMO market is experiencing a significant trend towards the adoption of modular manufacturing. This shift is characterized by the implementation of flexible facility designs that allow for rapid reconfiguration to accommodate a variety of cellular and gene therapies. Standardized, plug-and-play modules facilitate swift technology transfers and scalable capacity deployments while upholding stringent quality controls. Such an architectural approach enhances responsiveness to fluctuating client needs, reduces time to commercial readiness, and fosters a platform mindset that encourages repeatable processes and predictable project timelines, ultimately enabling firms to align their capacity with the evolving landscape of therapeutic modalities and strategic investments.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Advanced Therapy Medicinal Products CDMO Market Size by Therapy Type & CAGR (2026-2033)
- Market Overview
- Gene Therapy
- Viral Vectors
- Non-Viral Vectors
- Cell Therapy
- Autologous Therapies
- Allogeneic Therapies
- Tissue Engineered Products
- Combined ATMPs
- Others
Global Advanced Therapy Medicinal Products CDMO Market Size by Service Type & CAGR (2026-2033)
- Market Overview
- Process Development
- Analytical Development
- Clinical Manufacturing
- Commercial Manufacturing
- Fill-Finish Services
- Others
Global Advanced Therapy Medicinal Products CDMO Market Size by Application & CAGR (2026-2033)
- Market Overview
- Oncology
- Rare Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Others
Global Advanced Therapy Medicinal Products CDMO Market Size by Scale of Operation & CAGR (2026-2033)
- Market Overview
- Clinical Scale
- Commercial Scale
Global Advanced Therapy Medicinal Products CDMO Market Size & CAGR (2026-2033)
- North America (Therapy Type, Service Type, Application, Scale of Operation)
- US
- Canada
- Europe (Therapy Type, Service Type, Application, Scale of Operation)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Therapy Type, Service Type, Application, Scale of Operation)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Therapy Type, Service Type, Application, Scale of Operation)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Therapy Type, Service Type, Application, Scale of Operation)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Lonza Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Catalent
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi Advanced Therapies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sartorius Stedim Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AGC Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fujifilm Diosynth
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cellares
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Resilience
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Oxford Biomedica
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takara Bio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Techne
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ElevateBio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bluebird Bio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Legend Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Minaris Regenerative Medicine
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- KBI Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
